News

CRISPR‑engineered schistosomes secrete anti–SARS‑CoV‑2 C5‑Fc nanobodies. When released into the blood of infected mice, these nanobodies neutralized SARS‑CoV‑2 virions as effectively as – or more effectively than – national reference human convalescent serum. With existing controlled human infection models for schistosomes and other helminths, these findings support developing transgenic helminths as single‑dose delivery vehicles for therapeutic proteins.
Dr. Brindley and his collaborator’s recent paper was published in Nature Communications: “Heritable transgenic schistosomes as a living platform for SARS‑CoV‑2 neutralizing antibody secretion”

A heritable CRISPR knock-in in Schistosoma mansoni, a human blood fluke, generated a transgenic line that secreted a functional anti–SARS-CoV-2 antibody into the bloodstream of infected mice. Antibodies in the mice’s sera neutralized the virus, demonstrating the potential of engineered…

Subscribe to Featured News RSS Subscribe to News RSS Subscribe to Press Release RSS

Departments

Institutes

Resources

Getting Around

Initiatives